The Prevention of Cisplatin-Induced Nephrotoxicity: A General Consensus Statement of a Group of Oncologist-Hematologists, Adult and Pediatric Nephrologists, Radiation Oncologists, Clinical Pathologists, Clinical Pharmacologists, and Renal Physiologists on

Farzaneh Ashrafi, Mojgan Mortazavi, Mehdi Nematbakhsh

Abstract


Backgrounds: Most of the cancer patients with solid tumor are subjected to chemotherapy with cisplatin (CP) in clinic. However, the most side effect of CP is nephrotoxicity, which limits the treatment. The aim of study was to develop a general consensus statement for CP therapy in clinic to limit the drug-induced nephrotoxicity. Methods: A total of 30 oncologist-hematologists, adult and pediatric nephrologists, radiation oncologists, clinical pathologist clinical pharmacologist, and renal physiologist participated in a workshop, and in order to reduce the incidence of CP-induced nephrotoxicity, a general consensus was developed. Results: The developed general consensus was focused on some items such as age, sex, female hormone, nonsteroidal anti-inflammatory drugs (NSAID), renin–angiotensin system inhibitor drugs, glomerular filtration rate, hydration methods, contrasts, antioxidants, dextrose, and magnesium. Conclusion: The agreement between participants for CP therapy in clinic was achieved, and this general consensus was announced to be implemented in the hospitals.

Keywords


Cisplatin; consensus; nephron; toxicity

Full Text:

PDF

References


Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Lopez-Novoa JM,

Morales AI. An integrative view of the pathophysiological events

leading to cisplatin nephrotoxicity. Crit Rev Toxicol 2011;41:803-21.

de Jongh FE, van Veen RN, Veltman SJ, de Wit R,

van der Burg ME, van den Bent MJ, et al. Weekly high-dose

cisplatin is a feasible treatment option: Analysis on prognostic

factors for toxicity in 400 patients. B J Cancer 2003;88:1199-206.

Pezeshki Z, Maleki M, Talebi A, Nematbakhsh M. Age and

gender related renal side effects of cisplatin in animal model.

Asian Pac J Cancer Prev 2017;18:1703-5.

Ali BH, Al-Moundhri M, Tageldin M, Al Husseini IS,

Mansour MA, Nemmar A, et al. Ontogenic aspects of

cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol

;46:3355-9.

Nematbakhsh M, Pezeshki Z, Eshraghi Jazi F, Mazaheri B,

Moeini M, Safari T, et al. Cisplatin-induced nephrotoxicity;

protective supplements and gender differences. Asian Pac J

Cancer Prev 2017;18:295-314.

Aydin I, Agilli M, Aydin FN. Gender differences influence renal

injury in cisplatin-treated rats: Biochemical evaluation. Biol

Trace Elem Res 2014;158:275.

Nematbakhsh M, Ebrahimian S, Tooyserkani M, Eshraghi-Jazi F,

Talebi A, Ashrafi F. Gender difference in Cisplatin-induced

nephrotoxicity in a rat model: Greater intensity of damage in

male than female. Nephrourol Mon 2013;5:818-21.

Isnard-Bagnis C, Moulin B, Launay-Vacher V, Izzedine H,

Tostivint I, Deray G. [Anticancer drug-induced nephrotoxicity].

Nephrol Ther 2005;1:101-14.

Pezeshki Z, Nematbakhsh M, Nasri H, Talebi A, Pilehvarian AA,

Safari T, et al. Evidence against protective role of sex hormone

estrogen in Cisplatin-induced nephrotoxicity in ovarectomized

rat model. Toxicol Int 2013;20:43-7.

Karimi F, Kassaei S, Baradaran A, Ashrafi F, Talebi A, Lak Z,

et al. Dextrose hydration may promote cisplatin-induced

nephrotoxicity in rats: Gender-related difference. Indones

Biomed J 2019;11:136-44.

Jones DP, Spunt SL, Green D, Springate JE, Children’s

Oncology G. Renal late effects in patients treated for cancer in

childhood: A report from the Children’s oncology group. Pediatr

Blood Cancer 2008;51:724-31.

Kamel KM, Abd El-Raouf OM, Metwally SA, Abd El-Latif HA,

El-sayed ME. Hesperidin and rutin, antioxidant citrus flavonoids,

attenuate cisplatin-induced nephrotoxicity in rats. J Biochem Mol

Toxicol 2014;28:312-9.

Somani SM, Husain K, Whitworth C, Trammell GL, Malafa M,

Rybak LP. Dose-dependent protection by lipoic acid against

cisplatin-induced nephrotoxicity in rats: Antioxidant defense

system. Pharmacol Toxicol 2000;86:234-41.

Nematbakhsh M, Pezeshki Z. Sex-related difference in nitric

oxide metabolites levels after nephroprotectant supplementation

administration against cisplatin-induced nephrotoxicity in

wistar rat model: The role of vitamin E, erythropoietin, or

N-Acetylcysteine. ISRN Nephrol 2013;2013:612675.

Nematbakhsh M, Ashrafi F, Safari T, Talebi A, Nasri H,

Mortazavi M, et al. Administration of vitamin E and losartan as

prophylaxes in cisplatin-induced nephrotoxicity model in rats. J

Nephrol 2012;25:410-7.

Atasayar S, Gurer-Orhan H, Orhan H, Gurel B, Girgin G,

Ozgunes H. Preventive effect of aminoguanidine compared to

vitamin E and C on cisplatin-induced nephrotoxicity in rats. Exp

Toxicol Pathol 2009;61:23-32.

El Hamamsy M, Kamal N, Bazan NS, El Haddad M. Evaluation

of the effect of acetazolamide versus mannitol on cisplatininduced nephrotoxicity, a pilot study. Int J Clin Pharm

;40:1539-47.

Dhillon P, Amir E, Lo M, Kitchlu A, Chan C, Cochlin S, et al.

A case-control study analyzing mannitol dosing for prevention

of cisplatin-induced acute nephrotoxicity. J Oncol Pharm Pract

;25:875-83.

Adam JP, Fournier MA, Letarte N. Should mannitol be reinstated

in prevention of cisplatin-induced nephrotoxicity? J Oncol Pharm

Pract 2018;24:239-40.

Morgan KP, Buie LW, Savage SW. The role of mannitol as a

nephroprotectant in patients receiving cisplatin therapy. Ann

Pharmacother 2012;46:276-81.

Williams RP, Jr., Ferlas BW, Morales PC, Kurtzweil AJ.

Mannitol for the prevention of cisplatin-induced nephrotoxicity:

A retrospective comparison of hydration plus mannitol versus

hydration alone in inpatient and outpatient regimens at a large

academic medical center. J Oncol Pharm Pract 2017;23:422-8.

Launay-Vacher V, Isnard-Bagnis C, Janus N, Karie S, Deray G.

[Chemotherapy and renal toxicity]. Bull Cancer 2008;95 FMC

Onco:F96-103.

Zamani Z, Nematbakhsh M, Eshraghi-Jazi F, Talebi A,

Jilanchi S, Navidi M, et al. Effect of enalapril in cisplatininduced nephrotoxicity in rats; gender-related difference. Adv

Biomed Res 2016;5:14.

Haghighi M, Nematbakhsh M, Talebi A, Nasri H, Ashrafi F,

Roshanaei K, et al. The role of angiotensin II receptor 1 (AT1)

blockade in cisplatin-induced nephrotoxicity in rats: Genderrelated differences. Ren Fail 2012;34:1046-51.

Ghasemi M, Nematbakhsh M, Pezeshki Z, Soltani N,

Moeini M, Talebi A. Nephroprotective effect of estrogen and

progesterone combination on cisplatin-induced nephrotoxicity in

ovariectomized female rats. Indian J Nephrol 2016;26:167-75.

Pezeshki Z, Nematbakhsh M, Mazaheri S, Eshraghi-Jazi F,

Talebi A, Nasri H, et al. Estrogen abolishes protective effect

of erythropoietin against cisplatin-induced nephrotoxicity in

ovariectomized rats. ISRN Oncol 2012;2012:890310.

Nematbakhsh M, Pezeshki Z, Eshraghi-Jazi F, Ashrafi F,

Nasri H, Talebi A, et al. Vitamin E, vitamin C, or losartan is

not nephroprotectant against cisplatin-induced nephrotoxicity in

presence of estrogen in ovariectomized rat model. Int J Nephrol

;2012:284896.

Mazaheri S, Nematbakhsh M, Bahadorani M, Pezeshki Z,

Talebi A, Ghannadi AR, et al. Effects of fennel essential oil on

cisplatin-induced nephrotoxicity in ovariectomized rats. Toxicol

Int 2013;20:138-45.

Loh JM, Tran AL, Ji L, Groshen S, Daneshmand S,

Schuckman A, et al. Baseline glomerular filtration rate

and cisplatin- induced renal toxicity in urothelial cancer

patients. Clin Genitourinary Cancer 2017. doi: 10.1016/j.

clgc.2017.08.016.

Salek T, Vesely P, Bernatek J. Estimated glomerular filtration

rate in oncology patients before cisplatin chemotherapy. Klin

Onkol 2015;28:273-7.

Scott LA, Madan E, Valentovic MA. Influence of streptozotocin

(STZ)-induced diabetes, dextrose diuresis and acetone on

cisplatin nephrotoxicity in Fischer 344 (F344) rats. Toxicology

;60:109-25.

Fukushima K, Okada A, Oe H, Hirasaki M, Hamori M,

Nishimura A, et al. Pharmacokinetic-pharmacodynamic

analysis of cisplatin with hydration and mannitol diuresis: The

contribution of urine cisplatin concentration to nephrotoxicity.

Eur J Drug Metab Pharmacokinet 2018;43:193-203.

McKibbin T, Cheng LL, Kim S, Steuer CE, Owonikoko TK,

Khuri FR, et al. Mannitol to prevent cisplatin-induced

nephrotoxicity in patients with squamous cell cancer of the head

and neck (SCCHN) receiving concurrent therapy. Support Care

Cancer 2016;24:1789-93.

Chen MF, Yang CM, Su CM, Hu ML. Vitamin C protects against

cisplatin-induced nephrotoxicity and damage without reducing

its effectiveness in C57BL/6 mice xenografted with Lewis lung

carcinoma. NutrCancer 2014;66:1085-91.

Darwish MA, Abo-Youssef AM, Khalaf MM, Abo-Saif AA,

Saleh IG, Abdelghany TM. Vitamin E mitigates cisplatininduced nephrotoxicity due to reversal of oxidative/nitrosative

stress, suppression of inflammation and reduction of total renal

platinum accumulation. J Biochem Mol Toxicol 2017;31:1-9.

Durak I, Ozbek H, Karaayvaz M, Ozturk HS. Cisplatin induces

acute renal failure by impairing antioxidant system in guinea

pigs: Effects of antioxidant supplementation on the cisplatin

nephrotoxicity. Drug Chem Toxicol 2002;25:1-8.

Konishi H, Fujiwara H, Itoh H, Shiozaki A, Arita T, Kosuga T,

et al. Influence of magnesium and parathyroid hormone on

cisplatin-induced nephrotoxicity in esophageal squamous cell

carcinoma. Oncol Lett 2018;15:658-64.

Saito Y, Okamoto K, Kobayashi M, Narumi K, Furugen A,

Yamada T, et al. Magnesium co-administration decreases

cisplatin-induced nephrotoxicity in the multiple cisplatin

administration. Life Sci 2017;189:18-22.

Saito Y, Okamoto K, Kobayashi M, Narumi K, Yamada T,

Iseki K. Magnesium attenuates cisplatin-induced nephrotoxicity

by regulating the expression of renal transporters. Eur J

Pharmacol 2017;811:191-8.

Saito Y, Kobayashi M, Yamada T, Kasashi K, Honma R,

Takeuchi S, et al. Premedication with intravenous magnesium

has a protective effect against cisplatin-induced nephrotoxicity.

Support Care Cancer 2017;25:481-7.

Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K,

Takeda M, et al. Risk factors for cisplatin-induced nephrotoxicity

and potential of magnesium supplementation for renal protection.

PloS One 2014;9:e101902.

Yoshida T, Niho S, Toda M, Goto K, Yoh K, Umemura S, et al.

Protective effect of magnesium preloading on cisplatin-induced

nephrotoxicity: A retrospective study. Japanese J Clin Oncol

;44:346-54.

Soltani N, Nematbakhsh M, Eshraghi-Jazi F, Talebi A, Ashrafi F.

Effect of oral administration of magnesium on Cisplatin-induced

nephrotoxicity in normal and streptozocin-induced diabetic rats.

Nephrourol Mon 2013;5:884-90.

Ashrafi F, Haghshenas S, Nematbakhsh M, Nasri H, Talebi A,

Eshraghi-Jazi F, et al. The role of magnesium supplementation

in cisplatin-induced nephrotoxicity in a rat model: No

nephroprotectant effect. Int J Prev Med 2012;3:637-43.

Goren MP. Cisplatin nephrotoxicity affects magnesium and

calcium metabolism. Med Pediatr Oncol 2003;41:186-9.